Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORADUR-Methylphenidate in Children and Adolescents With ADHD
NCT02450890Phase 3Completed
- Sponsor
- Orient Pharma Co., Ltd.
- Start
- Jun 2015
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of methylphenidate in attention deficit hyperactivity disorder (ADHD), sponsored by Orient Pharma Co., Ltd.. Started Jun 2015; status: completed.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT02450890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02450890.